Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
THAR
Tharimmune, Inc.
THAR's pipeline includes bispecific antibodies (HS1940, HS3215), aligning with Bispecific Antibodies.
|
$23.83M |
$4.74
-5.58%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$23.64M |
$1.70
-9.57%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$23.47M |
$1.09
-0.45%
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$22.35M |
$0.20
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$20.88M |
$0.86
-3.23%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$20.81M |
$1.51
-3.82%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$20.59M |
$3.63
+12.73%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$20.16M |
$0.61
-1.05%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$19.82M |
$0.31
+14.98%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$19.45M |
$1.22
-1.61%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$18.71M |
$0.91
-2.03%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$18.08M |
$0.37
-17.91%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$17.82M |
$0.87
+1.23%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$17.48M |
$0.08
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$16.46M |
$2.71
+0.74%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$16.09M |
$1.50
-4.78%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$15.34M |
$13.81
-3.19%
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$15.20M |
$0.40
|
|
OTLC
Oncotelic Therapeutics, Inc.
Oncotelic's core oncology program OT-101 and nanoparticle platform place it squarely in oncology-focused biotech.
|
$15.13M |
$0.04
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$15.05M |
$0.43
+7.70%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$14.92M |
$1.28
+1.18%
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$14.83M |
$0.11
+4.37%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$14.19M |
$0.40
-0.69%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$13.98M |
$0.71
-1.33%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$13.89M |
$1.30
+2.76%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$13.81M |
$3.15
-0.16%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$13.49M |
$2.42
-5.27%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$13.39M |
$1.00
-3.37%
|
|
TRIB
Trinity Biotech plc
Includes companion diagnostics/biomarker-guided tests as part of its oncology-focused diagnostic portfolio.
|
$13.39M |
$0.73
+4.99%
|
|
BIAF
bioAffinity Technologies, Inc.
The business focuses on oncology diagnostics (early detection of lung cancer).
|
$12.87M |
$2.83
+2.54%
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$12.79M |
$2.43
+1.67%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$12.78M |
$0.45
+0.02%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$12.73M |
$0.61
-0.98%
|
Showing page 21 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
